CV Science

Stefania Millevoi Team Leader, Cancer Research Center of Toulouse, INSERM, France

Course and current status

Currently:        Team Leader

Cancer Research Center of Toulouse (CRCT), INSERM U1037, Toulouse, FR

2011-2015:      Principal Investigator, Senior Associate Professor, CR1

Cancer Research Center of Toulouse (CRCT), INSERM U1037, Toulouse, FR

2005-2011:      Principal Investigator, Junior Associate Professor, CR2

INSERM, Institut Claudius Regaud (ICR), Toulouse, FR

2001-2005:      Post-doctoral Fellow

Institut Claudius Regaud, INSERM, Toulouse, FR

1998-2001:      Post-doctoral Fellow

Institut of Pharmacology and structural biology (IPBS), Toulouse, FR

1996-1998:      Post-doctoral Fellow

European Molecular Biology Laboratory, Heidelberg, DE

1993-1996:      PhD in Biochemistry and Structural biology

« La Sapienza » University, Rome, IT

European Molecular Biology Laboratory, Heidelberg, DE

Scientific summary

During my PostDoc and CR position at INSERM, my research activity focused on RNA cis-elements/structures (including RNA G-quadruplexes) and RNA-binding proteins (including U2AF, PTB, hnRNP A1, hnRNP HF) acting as modulators of post-transcriptional gene expression (including RNA processing and translation) of disease-relevant genes (β-globin involved in β-thalassaemia; BRCA1, MSH6, p53, VEGF in cancer). 

Our team program at CRCT focuses on understanding the role of RBPs in post-transcriptional gene expression reprogramming in response to genotoxic stress and to the deregulation associated to cancer pathobiology and response/resistance to treatments. Specifically, we are interested in investigating the mechanisims underlying  post-transcriptional gene expression regulation in glioblastoma, the most common and aggressive type of brain tumor.  

We explore the role of RNA-protein interactions in cancer by integrating multiple layers of information based on multidisciplinary approaches, including

1) molecular mechanisms of regulation

2) genome-wide analysis of post-transcriptional regulations and of RNA-protein interactions 3) pre-clinical in vitro (spheroids) and in vivo analysis (xenografts models) and

4) clinical data from patients (Tissue microarray, TMA).

We are also interested in developing small molecules that target cancer relevant post-transcriptional processes directed by specific RNA-protein interactions.